Log In Sign up
The largest database of trusted experimental protocols

Cyclin d3 ab28283 antibody

Manufactured by Abcam
Visit Supplier

Cyclin D3 (ab28283) is a rabbit monoclonal antibody that recognizes the Cyclin D3 protein. Cyclin D3 is a regulatory subunit of the cyclin-dependent kinase complex, which plays a crucial role in cell cycle progression. This antibody can be used for various research applications, including Western blotting, immunoprecipitation, and immunohistochemistry.

Automatically generated - may contain errors

Lab products found in correlation

Abemaciclib, by Selleck Chemicals (2 mentions) Antibodies against cyclin d2 d52f9 and p rb s795, by Cell Signaling Technology (2 mentions) Antibody against rb 554136, by BD (2 mentions) Palbociclib s1116, by Selleck Chemicals (1 mentions) C fos e 8, by Santa Cruz Biotechnology (1 mentions) Ribociclib, by Selleck Chemicals (1 mentions) Palbociclib, by Selleck Chemicals (1 mentions)

Close spelling variants of this product

Cyclin D3 Ab28283

2 protocols using cyclin d3 ab28283 antibody

1

Cell Cycle Regulation Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Palbociclib (S1116) and Abemaciclib (S7158) were purchased from Selleck Chemicals (Houston, Texas, USA). Antibodies against HSP90 (H-114), cyclin D1 (A12), CDK6 (C-21), CDK4 (DCS-35), p16 (C-20), p21 (H164), cyclin E (HE12), c-Jun (G4) and c-Fos (E8) were from Santa Cruz Biotechnology; antibodies against cyclin D2 (D52F9) and p-RB (S795) were from Cell Signaling; antibody against SMARCA4 were from Bethyl Laboratories (A300-813A). Antibody against Rb (554136) was from BD Pharmingen. Cyclin D3 (ab28283) antibody was from Abcam. Antibody against SMARCA4 was used with 1:5000 dilution and all others with 1:1000 dilution. Antibodies for IHC and ChIP are listed in the corresponding method section below.
Xue Y., Meehan B., Fu Z., Wang X.Q., Fiset P.O., Rieker R., Levins C., Kong T., Zhu X., Morin G., Skerritt L., Herpel E., Venneti S., Martinez D., Judkins A.R., Jung S., Camilleri-Broet S., Gonzalez A.V., Guiot M.C., Lockwood W.W., Spicer J.D., Agaimy A., Pastor W.A., Dostie J., Rak J., Foulkes W.D, & Huang S. (2019). SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications, 10, 557.
+ Open protocol
+ Expand
2

Evaluation of CDK inhibitors in cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Palbociclib (S1116), Abemaciclib (S7158), and Ribociclib (S7440) were purchased from Selleck Chemicals (Houston, TX, USA). Antibodies against HSP90 (H-114), Cyclin D1 (M20), CDK6 (C-21), CDK4 (DCS-35), p16 (C-20), p21 (H164), p27 (C19), and cyclin E (HE12) were from Santa Cruz Biotechnology; antibodies against Cyclin D2 (D52F9) and p-RB (S795) were from Cell Signaling; antibody against SMARCA4 were from Bethyl Laboratories (A300-813A). Antibody against RB (554136) was from BD Pharmingen. Cyclin D3 (ab28283) antibody was from Abcam. Antibody against SMARCA4 was used with 1:5000 dilution and all others with 1:1000 dilution. Antibodies for IHC are listed in the corresponding method section below.
Xue Y., Meehan B., Macdonald E., Venneti S., Wang X.Q., Witkowski L., Jelinic P., Kong T., Martinez D., Morin G., Firlit M., Abedini A., Johnson R.M., Cencic R., Patibandla J., Chen H., Papadakis A.I., Auguste A., de Rink I., Kerkhoven R.M., Bertos N., Gotlieb W.H., Clarke B.A., Leary A., Witcher M., Guiot M.C., Pelletier J., Dostie J., Park M., Judkins A.R., Hass R., Levine D.A., Rak J., Vanderhyden B., Foulkes W.D, & Huang S. (2019). CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 10, 558.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!